Followers | 839 |
Posts | 120661 |
Boards Moderated | 13 |
Alias Born | 09/05/2002 |
Thursday, October 27, 2022 9:25:30 AM
“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”
Recent MRK News
- U.S. Index Futures Decline; Oil Prices Rise on Strong Demand and OPEC+ Production Outlook • IH Market News • 10/31/2024 11:15:53 AM
- Microsoft and Meta Decline Up to 4%; Roku Falls 14% Amid Lower Estimates; Booking Surges 6%; Carvana Soars 20% • IH Market News • 10/31/2024 11:13:28 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/31/2024 10:44:02 AM
- Merck Announces Third-Quarter 2024 Financial Results • Business Wire • 10/31/2024 10:30:00 AM
- Merck and Moderna Initiate Phase 3 Trial Evaluating Adjuvant V940 (mRNA-4157) in Combination with KEYTRUDA® (pembrolizumab) After Neoadjuvant KEYTRUDA and Chemotherapy in Patients With Certain Types of Non-Small Cell Lung Cancer (NSCLC) • Business Wire • 10/28/2024 10:45:00 AM
- Merck’s KEYTRUDA® (pembrolizumab) Receives 30th Approval From European Commission With Two New Indications in Gynecologic Cancers • Business Wire • 10/24/2024 10:45:00 AM
- CDC’S ACIP Recommends Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) for Pneumococcal Vaccination in Adults 50 Years of Age and Older • Business Wire • 10/23/2024 11:58:00 PM
- Higher Treasury Yields May Lead To Extended Pullback On Wall Street • IH Market News • 10/22/2024 01:08:50 PM
- US Futures Slip as Investors Eye Q3 Earnings; Oil Prices Drop • IH Market News • 10/22/2024 10:08:22 AM
- Dow Gives Back Ground But Nasdaq Closes In Positive Territory • IH Market News • 10/21/2024 08:44:00 PM
- Gilead and Merck Announce Phase 2 Data Showing a Treatment Switch to an Investigational Oral Once-Weekly Combination Regimen of Islatravir and Lenacapavir Maintained Viral Suppression in Adults at Week 48 • Business Wire • 10/19/2024 09:09:00 PM
- Merck’s Clesrovimab (MK-1654), an Investigational Respiratory Syncytial Virus (RSV) Preventative Monoclonal Antibody, Significantly Reduced Incidence of RSV Disease and Hospitalization in Healthy Preterm and Full-term Infants • Business Wire • 10/17/2024 10:00:00 PM
- Merck’s CAPVAXIVE™ (Pneumococcal 21-valent Conjugate Vaccine) Demonstrates Positive Immune Responses in Adults with Increased Risk for Pneumococcal Disease • Business Wire • 10/16/2024 10:45:00 AM
- Exelixis and Merck Sign Clinical Development Collaboration to Evaluate Investigational Zanzalintinib in Combination with KEYTRUDA® (pembrolizumab) in Head and Neck Cancer and in Combination with WELIREG® (belzutifan) in Renal Cell Carcinoma • Business Wire • 10/14/2024 12:00:00 PM
- New Data to be Presented at IDWeek 2024 Reinforce Merck’s Broad and Diverse Vaccines and Infectious Disease Pipeline and Portfolio • Business Wire • 10/09/2024 10:45:00 AM
- Merck’s KEYTRUDA® (pembrolizumab) Met Primary Endpoint of Event-Free Survival (EFS) as Perioperative Treatment Regimen in Patients With Resected, Locally Advanced Head and Neck Squamous Cell Carcinoma • Business Wire • 10/08/2024 10:45:00 AM
- Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • InvestorsHub NewsWire • 10/03/2024 12:45:00 PM
- Beyond the Horizon: Innovative Drug Combinations Offer New Hope for Alzheimer's and More • PR Newswire (US) • 10/03/2024 12:30:00 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 06:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 06:10:35 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 10/01/2024 06:06:03 PM
- Merck Completes Acquisition of Investigational B-Cell Depletion Therapy, CN201, from Curon Biopharmaceutical • Business Wire • 10/01/2024 10:45:00 AM
- Merck to Hold Third-Quarter 2024 Sales and Earnings Conference Call Oct. 31 • Business Wire • 10/01/2024 10:30:00 AM
- Merck to Present New Long-Term Data for Tulisokibart (MK-7240), an Investigational Anti-TL1A Monoclonal Antibody, in Inflammatory Bowel Disease at UEG Week 2024 • Business Wire • 09/26/2024 10:45:00 AM
- Merck Provides Update on Phase 3 KEYFORM-007 Trial Evaluating Investigational Fixed-Dose Combination of Favezelimab and Pembrolizumab for Patients With Previously Treated PD-L1 Positive Microsatellite Stable Metastatic Colorectal Cancer • Business Wire • 09/25/2024 10:45:00 AM
CBD Life Sciences Inc. (CBDL) Launches High-Demand Mushroom Gummy Line for Targeted Wellness Needs, Tapping into a Booming $20 Billion Market • CBDL • Oct 31, 2024 8:00 AM
Nerds On Site Announces Q1 Growth and New Initiatives for the Remainder of 2024 • NOSUF • Oct 31, 2024 7:01 AM
Innovation Beverage Group Receives Largest Shipment of its Top-Selling Bitters to Date in the U.S.-Ready to Meet Growing Demand from Expanding Distribution Network • IBG • Oct 30, 2024 12:22 PM
Element79 Gold Corp to Update Investors on the Emerging Growth Conference on October 31, 2024 • ELMGF • Oct 30, 2024 9:08 AM
CBD Life Sciences Inc. (CBDL) Announces Grand View Research Report Findings on High - Growth CBD Equine Market, Aiming to Drive Unprecedented Shareholder Value • CBDL • Oct 29, 2024 10:19 AM
Integrated Ventures Announces Partnership And Lease Agreement with Driptide Wellness - Leading Health and Wellness Provider. • INTV • Oct 29, 2024 8:45 AM